JP2007500719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500719A5 JP2007500719A5 JP2006522095A JP2006522095A JP2007500719A5 JP 2007500719 A5 JP2007500719 A5 JP 2007500719A5 JP 2006522095 A JP2006522095 A JP 2006522095A JP 2006522095 A JP2006522095 A JP 2006522095A JP 2007500719 A5 JP2007500719 A5 JP 2007500719A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- group
- independently selected
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 80
- VGYSWOQZWCAVQZ-UHFFFAOYSA-N 5-bromo-n-(2-cyclopropylethyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridine-3-sulfonamide Chemical compound FC1=CC=C(C(F)(F)F)C(C(=O)N2CCN(CC2)C=2C(=CC(=CN=2)S(=O)(=O)NCCC2CC2)Br)=C1 VGYSWOQZWCAVQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 119
- 239000001257 hydrogen Substances 0.000 claims 119
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 77
- 125000000753 cycloalkyl group Chemical group 0.000 claims 73
- 125000000217 alkyl group Chemical group 0.000 claims 71
- 125000003710 aryl alkyl group Chemical group 0.000 claims 71
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 68
- 125000000623 heterocyclic group Chemical group 0.000 claims 68
- 125000001072 heteroaryl group Chemical group 0.000 claims 65
- 125000003118 aryl group Chemical group 0.000 claims 59
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 50
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 47
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 43
- 150000002431 hydrogen Chemical class 0.000 claims 42
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 36
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 36
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 30
- -1 bromo, fluoro, chloro, methyl Chemical group 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 16
- 125000003367 polycyclic group Chemical group 0.000 claims 15
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 14
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 230000005856 abnormality Effects 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 102000055981 human SCD1 Human genes 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 1
- BWHQNZKTIFGBIY-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(F)=CC=C1CNC(=O)NC1=CC=C(N2CCN(CC2)C(=O)C=2C(=CC=CC=2)C(F)(F)F)N=C1 BWHQNZKTIFGBIY-UHFFFAOYSA-N 0.000 claims 1
- SHIBQVFGKOYTOZ-UHFFFAOYSA-N 1-[6-[4-(cyclohexanecarbonyl)piperazin-1-yl]pyridin-3-yl]-3-pentylurea Chemical compound N1=CC(NC(=O)NCCCCC)=CC=C1N1CCN(C(=O)C2CCCCC2)CC1 SHIBQVFGKOYTOZ-UHFFFAOYSA-N 0.000 claims 1
- VJXYOPYNLAFVLT-UHFFFAOYSA-N 1-[6-[4-(cyclopentanecarbonyl)piperazin-1-yl]pyridin-3-yl]-3-pentylurea Chemical compound N1=CC(NC(=O)NCCCCC)=CC=C1N1CCN(C(=O)C2CCCC2)CC1 VJXYOPYNLAFVLT-UHFFFAOYSA-N 0.000 claims 1
- MSAJNTURICXWMG-UHFFFAOYSA-N 1-benzyl-3-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]urea Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=CC(NC(=O)NCC=3C=CC=CC=3)=CC=2)CC1 MSAJNTURICXWMG-UHFFFAOYSA-N 0.000 claims 1
- SETHYFAYGJYELK-UHFFFAOYSA-N 1-butyl-3-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]urea Chemical compound N1=CC(NC(=O)NCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 SETHYFAYGJYELK-UHFFFAOYSA-N 0.000 claims 1
- OWQDTUMYACMNPZ-UHFFFAOYSA-N 1-pentyl-3-[6-[4-(pyridine-2-carbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound N1=CC(NC(=O)NCCCCC)=CC=C1N1CCN(C(=O)C=2N=CC=CC=2)CC1 OWQDTUMYACMNPZ-UHFFFAOYSA-N 0.000 claims 1
- NFJJLEVUQMOBTC-UHFFFAOYSA-N 1-pentyl-3-[6-[4-(pyridine-4-carbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound N1=CC(NC(=O)NCCCCC)=CC=C1N1CCN(C(=O)C=2C=CN=CC=2)CC1 NFJJLEVUQMOBTC-UHFFFAOYSA-N 0.000 claims 1
- UTUFVPXFZZZFGN-UHFFFAOYSA-N 1-pentyl-3-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]urea Chemical compound N1=CC(NC(=O)NCCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 UTUFVPXFZZZFGN-UHFFFAOYSA-N 0.000 claims 1
- DYGCSVJUSRRMNV-UHFFFAOYSA-N 3-phenyl-n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]propanamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=CC(NC(=O)CCC=3C=CC=CC=3)=CC=2)CC1 DYGCSVJUSRRMNV-UHFFFAOYSA-N 0.000 claims 1
- PMPRNHCEJRGQER-UHFFFAOYSA-N 3-phenyl-n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]propane-1-sulfonamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=CC(NS(=O)(=O)CCCC=3C=CC=CC=3)=CC=2)CC1 PMPRNHCEJRGQER-UHFFFAOYSA-N 0.000 claims 1
- DWLBJBPXPZTHRL-UHFFFAOYSA-N 4-methyl-n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]pentanamide Chemical compound N1=CC(NC(=O)CCC(C)C)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 DWLBJBPXPZTHRL-UHFFFAOYSA-N 0.000 claims 1
- MRZOEVPTAGFNBJ-UHFFFAOYSA-N CC(C1=CC=CC=C1)NC(NC1=CC=C(N(CC2)CCN2C(C2=C(C(F)(F)F)C=CC=C2)=O)N=C1)=O Chemical compound CC(C1=CC=CC=C1)NC(NC1=CC=C(N(CC2)CCN2C(C2=C(C(F)(F)F)C=CC=C2)=O)N=C1)=O MRZOEVPTAGFNBJ-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- XCXZTLXCCYWIHM-UHFFFAOYSA-N n-(2-cyclopropylethyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridine-3-sulfonamide Chemical compound FC1=CC=C(C(F)(F)F)C(C(=O)N2CCN(CC2)C=2N=CC(=CC=2)S(=O)(=O)NCCC2CC2)=C1 XCXZTLXCCYWIHM-UHFFFAOYSA-N 0.000 claims 1
- LYUAIDPXQPEPAN-UHFFFAOYSA-N n-[6-[2-oxo-4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]-4-phenylbutanamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CC(=O)N(C=2N=CC(NC(=O)CCCC=3C=CC=CC=3)=CC=2)CC1 LYUAIDPXQPEPAN-UHFFFAOYSA-N 0.000 claims 1
- LWZBMBILYPQPLU-UHFFFAOYSA-N n-[6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl]heptanamide Chemical compound N1=CC(NC(=O)CCCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=C(Cl)C=2)Cl)CC1 LWZBMBILYPQPLU-UHFFFAOYSA-N 0.000 claims 1
- YSRJBLAQQFNIFF-UHFFFAOYSA-N n-[6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl]hexane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=C(Cl)C=2)Cl)CC1 YSRJBLAQQFNIFF-UHFFFAOYSA-N 0.000 claims 1
- OTLZKWOIKPHLAG-UHFFFAOYSA-N n-[6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl]pentane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=C(Cl)C=2)Cl)CC1 OTLZKWOIKPHLAG-UHFFFAOYSA-N 0.000 claims 1
- GTDXQDLDSBIWGE-UHFFFAOYSA-N n-[6-[4-(2-bromobenzoyl)piperazin-1-yl]pyridin-3-yl]pentane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)Br)CC1 GTDXQDLDSBIWGE-UHFFFAOYSA-N 0.000 claims 1
- KDXJVMPAIXDGML-UHFFFAOYSA-N n-[6-[4-(cyclohexanecarbonyl)piperazin-1-yl]pyridin-3-yl]cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NC(C=N1)=CC=C1N(CC1)CCN1C(=O)C1CCCCC1 KDXJVMPAIXDGML-UHFFFAOYSA-N 0.000 claims 1
- YHZAMSOVDNMGLC-UHFFFAOYSA-N n-[6-[4-(naphthalene-1-carbonyl)piperazin-1-yl]pyridin-3-yl]hexane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCCC)=CC=C1N1CCN(C(=O)C=2C3=CC=CC=C3C=CC=2)CC1 YHZAMSOVDNMGLC-UHFFFAOYSA-N 0.000 claims 1
- YTTGWVXQNYROBJ-UHFFFAOYSA-N n-[6-[4-(naphthalene-1-carbonyl)piperazin-1-yl]pyridin-3-yl]pentane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCC)=CC=C1N1CCN(C(=O)C=2C3=CC=CC=C3C=CC=2)CC1 YTTGWVXQNYROBJ-UHFFFAOYSA-N 0.000 claims 1
- SKVZSPBXGPHGKS-UHFFFAOYSA-N n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]butane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 SKVZSPBXGPHGKS-UHFFFAOYSA-N 0.000 claims 1
- ANKMEDVQGBWVNU-UHFFFAOYSA-N n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]heptanamide Chemical compound N1=CC(NC(=O)CCCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 ANKMEDVQGBWVNU-UHFFFAOYSA-N 0.000 claims 1
- XXUQOIASRQOUAG-UHFFFAOYSA-N n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]hexanamide Chemical compound N1=CC(NC(=O)CCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 XXUQOIASRQOUAG-UHFFFAOYSA-N 0.000 claims 1
- CEUVRTXEJIZJNR-UHFFFAOYSA-N n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]hexane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 CEUVRTXEJIZJNR-UHFFFAOYSA-N 0.000 claims 1
- NIESZWJHNKBXSD-UHFFFAOYSA-N n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridin-3-yl]pentane-1-sulfonamide Chemical compound N1=CC(NS(=O)(=O)CCCCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 NIESZWJHNKBXSD-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- MONRWRVYLOHUFA-UHFFFAOYSA-N pentylurea Chemical compound CCCCCNC(N)=O MONRWRVYLOHUFA-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 16
- 239000002585 base Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000012267 brine Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZOGZOXRETBBBJI-UHFFFAOYSA-N 2-cyclopropylethanamine Chemical compound NCCC1CC1 ZOGZOXRETBBBJI-UHFFFAOYSA-N 0.000 description 1
- WOJIIXQKYCQUIZ-UHFFFAOYSA-N 5-bromo-6-chloro-n-(2-cyclopropylethyl)pyridine-3-sulfonamide Chemical compound C1=C(Br)C(Cl)=NC=C1S(=O)(=O)NCCC1CC1 WOJIIXQKYCQUIZ-UHFFFAOYSA-N 0.000 description 1
- TURGMVYIESHZBE-UHFFFAOYSA-N 5-bromo-6-chloropyridine-3-sulfonyl chloride Chemical compound ClC1=NC=C(S(Cl)(=O)=O)C=C1Br TURGMVYIESHZBE-UHFFFAOYSA-N 0.000 description 1
- ZKHVSNDPPPJHTM-UHFFFAOYSA-N [5-fluoro-2-(trifluoromethyl)phenyl]-piperazin-1-ylmethanone Chemical compound FC1=CC=C(C(F)(F)F)C(C(=O)N2CCNCC2)=C1 ZKHVSNDPPPJHTM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49111803P | 2003-07-30 | 2003-07-30 | |
| US49111603P | 2003-07-30 | 2003-07-30 | |
| US49134003P | 2003-07-30 | 2003-07-30 | |
| US60/491,340 | 2003-07-30 | ||
| US60/491,118 | 2003-07-30 | ||
| US60/491,116 | 2003-07-30 | ||
| PCT/US2004/024657 WO2005011656A2 (en) | 2003-07-30 | 2004-07-29 | Pyridyl derivatives and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007500719A JP2007500719A (ja) | 2007-01-18 |
| JP2007500719A5 true JP2007500719A5 (enExample) | 2007-09-13 |
| JP4782008B2 JP4782008B2 (ja) | 2011-09-28 |
Family
ID=34119804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522095A Expired - Fee Related JP4782008B2 (ja) | 2003-07-30 | 2004-07-29 | ピリジル誘導体および治療剤としてのその用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7605161B2 (enExample) |
| EP (2) | EP2316825A1 (enExample) |
| JP (1) | JP4782008B2 (enExample) |
| KR (1) | KR20060036106A (enExample) |
| AU (2) | AU2004261267B9 (enExample) |
| BR (1) | BRPI0412352A (enExample) |
| CA (1) | CA2533900A1 (enExample) |
| EC (1) | ECSP066312A (enExample) |
| ES (1) | ES2397389T3 (enExample) |
| IL (1) | IL173398A0 (enExample) |
| MA (1) | MA28008A1 (enExample) |
| NO (1) | NO20060972L (enExample) |
| SG (1) | SG145700A1 (enExample) |
| TN (1) | TNSN06036A1 (enExample) |
| WO (1) | WO2005011656A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| SG145695A1 (en) * | 2003-07-29 | 2008-09-29 | Xenon Pharmaceuticals Inc | Pyridyl derivatives and their use as therapeutic agents |
| TW200606137A (en) * | 2004-07-02 | 2006-02-16 | Sankyo Co | Urea derivatives |
| WO2006034341A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| JP4958787B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体 |
| CA2580855A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
| BRPI0515482A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seus usos como agentes terapêuticos |
| AR051026A1 (es) | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| HUE039584T2 (hu) | 2004-10-29 | 2019-01-28 | Kalypsys Inc | PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek |
| JP2008521847A (ja) * | 2004-12-03 | 2008-06-26 | エフ．ホフマン−ラ ロシュ アーゲー | Ｈ３拮抗剤としての３−置換ピリジン誘導体 |
| WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
| HUE040020T2 (hu) | 2005-10-25 | 2019-02-28 | Kalypsys Inc | PPAR modulátorok sói és eljárások metabolikus betegségek kezelésére |
| WO2007071023A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| PA8713501A1 (es) | 2006-02-07 | 2009-09-17 | Wyeth Corp | INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1 |
| WO2007136746A2 (en) * | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
| RU2491285C2 (ru) | 2006-06-05 | 2013-08-27 | Новартис Аг | Органические соединения |
| AU2007288245A1 (en) | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
| KR20090083477A (ko) * | 2006-11-20 | 2009-08-03 | 그렌마크 파머수티칼스 에스. 아. | 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체 |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| DK2142529T3 (da) | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| WO2009019566A1 (en) | 2007-08-08 | 2009-02-12 | Pfizer Inc. | Phenoxy-pyrrolidine derivative and its use and compositions |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| CA2719721C (en) | 2008-03-26 | 2012-12-18 | Daiichi Sankyo Company, Limited | Tetrahydroisoquinoline derivative |
| US8673917B2 (en) | 2008-09-09 | 2014-03-18 | Sanofi | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors |
| US20100160323A1 (en) * | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
| JP5597210B2 (ja) | 2009-02-17 | 2014-10-01 | メルク カナダ インコーポレイテッド | ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤として有用な新規スピロ化合物 |
| EP2414366A1 (en) * | 2009-04-01 | 2012-02-08 | Novartis AG | Spiro derivatives for the modulation of stearoyl-coa desaturase |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| US20130012709A1 (en) | 2009-09-10 | 2013-01-10 | Centre National De La Recherche Scientifique | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
| SG10201605163PA (en) | 2011-06-22 | 2016-08-30 | Purdue Pharma Lp | Trpv1 antagonists including dihydroxy substituent and uses thereof |
| JP6293127B2 (ja) | 2012-05-22 | 2018-03-14 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | 未分化細胞の選択的阻害剤 |
| MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
| EP3566055B1 (en) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd inhibitor for the treatment of neurological disorders |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| ES2970881T3 (es) * | 2018-11-14 | 2024-05-31 | Allinky Biopharma | Compuestos de piridin-sulfonamida para el tratamiento de afecciones relacionadas con interleucina 1 beta |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996318A (en) * | 1987-04-03 | 1991-02-26 | The Upjohn Company | Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke |
| CA1338012C (en) * | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
| US4994456A (en) * | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
| JP2502824B2 (ja) | 1991-03-13 | 1996-05-29 | 松下電器産業株式会社 | 平面型誘電体フィルタ |
| JP2503198Y2 (ja) | 1991-06-17 | 1996-06-26 | 株式会社椿本チエイン | 搬送方向に傾動可能なワ―ク回動ア―ムを具えたワ―ク搬送装置 |
| JP2002539187A (ja) * | 1999-03-17 | 2002-11-19 | アストラゼネカ アクチボラグ | アミド誘導体 |
| AU779550B2 (en) * | 1999-04-09 | 2005-01-27 | Meiji Seika Kaisha Ltd. | Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same |
| AU1887401A (en) * | 1999-12-14 | 2001-06-25 | Nippon Shinyaku Co. Ltd. | Medicinal composition |
| PT1315831E (pt) | 2000-02-24 | 2010-11-04 | Xenon Pharmaceuticals Inc | Estearoil-coa dessaturase para identificar agentes terapêuticos que reduzem triglicéridos |
| CA2403017A1 (en) * | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| CA2430987A1 (en) | 2000-09-26 | 2002-04-04 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
| US20020169166A1 (en) | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
| US7196080B2 (en) * | 2001-06-15 | 2007-03-27 | Astellas Pharma Inc. | Phenylpyridinecarbonylpiperazinederivative |
| US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
| WO2003045921A1 (en) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
| CN1628109A (zh) * | 2002-02-05 | 2005-06-15 | 诺沃挪第克公司 | 新颖的芳基－与杂芳基－哌嗪 |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| KR20040090979A (ko) | 2002-03-13 | 2004-10-27 | 얀센 파마슈티카 엔.브이. | 히스톤 데아세틸레이즈의 신규한 억제제 |
| JP4725945B2 (ja) | 2002-03-13 | 2011-07-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体 |
| AU2003221786A1 (en) * | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| US7582761B2 (en) * | 2002-10-17 | 2009-09-01 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2004203871A (ja) * | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
| SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| SG145695A1 (en) * | 2003-07-29 | 2008-09-29 | Xenon Pharmaceuticals Inc | Pyridyl derivatives and their use as therapeutic agents |
| KR20060037409A (ko) * | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피페라진 유도체 및 그의 치료제로서의 용도 |
-
2004
- 2004-07-29 EP EP10184703A patent/EP2316825A1/en not_active Withdrawn
- 2004-07-29 BR BRPI0412352-2A patent/BRPI0412352A/pt not_active IP Right Cessation
- 2004-07-29 AU AU2004261267A patent/AU2004261267B9/en not_active Ceased
- 2004-07-29 WO PCT/US2004/024657 patent/WO2005011656A2/en not_active Ceased
- 2004-07-29 US US10/566,193 patent/US7605161B2/en not_active Expired - Fee Related
- 2004-07-29 EP EP04779655A patent/EP1651606B1/en not_active Expired - Lifetime
- 2004-07-29 CA CA002533900A patent/CA2533900A1/en not_active Abandoned
- 2004-07-29 KR KR1020067002002A patent/KR20060036106A/ko not_active Ceased
- 2004-07-29 SG SG200805679-8A patent/SG145700A1/en unknown
- 2004-07-29 ES ES04779655T patent/ES2397389T3/es not_active Expired - Lifetime
- 2004-07-29 JP JP2006522095A patent/JP4782008B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-25 EC EC2006006312A patent/ECSP066312A/es unknown
- 2006-01-26 IL IL173398A patent/IL173398A0/en unknown
- 2006-01-27 TN TNP2006000036A patent/TNSN06036A1/en unknown
- 2006-02-27 MA MA28836A patent/MA28008A1/fr unknown
- 2006-02-28 NO NO20060972A patent/NO20060972L/no not_active Application Discontinuation
-
2009
- 2009-05-11 AU AU2009201861A patent/AU2009201861A1/en not_active Abandoned
- 2009-09-02 US US12/552,868 patent/US8153636B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500719A5 (enExample) | ||
| JP2007500716A5 (enExample) | ||
| TW444013B (en) | Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia | |
| JP5057625B2 (ja) | ３−ヒドロキシピコリン酸誘導体の調製方法 | |
| TWI447120B (zh) | 噻吩并三唑并苯二氮呯化合物、其醫藥上之用途 | |
| JP4833080B2 (ja) | １−ピペラジン−および１−ホモピペラジン−カルボキシレートの誘導体、その調製方法、およびｆａａｈ酵素の阻害剤としてのその使用 | |
| JP3260458B2 (ja) | 新規ベンゾピラン誘導体 | |
| JP6409004B2 (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| JP5646082B2 (ja) | Ｈｄｌコレステロール上昇剤としてのオキシム化合物 | |
| JP2007500715A5 (enExample) | ||
| EA012589B1 (ru) | Производные фениламида 4-(бензил)пиперазин-1-карбоновой кислоты и родственные соединения в качестве модуляторов амида жирной кислоты гидролазы для лечения страхов, боли и других состояний | |
| US8940731B2 (en) | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | |
| KR20180100697A (ko) | Ror-감마의 조절제로서의 벤즈이미다졸 유도체 | |
| JP2016535784A5 (enExample) | ||
| CA2102137A1 (en) | Heterocyclic compounds | |
| RS58786B1 (sr) | Novi aminski derivati ili njihove soli kao inhibitori tnf alfa | |
| US7288658B2 (en) | Process for preparation of pyridine derivatives | |
| CN101838271A (zh) | 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物 | |
| JP7428833B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
| JP2013502447A (ja) | 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体 | |
| US5750699A (en) | Method of preparing certain 3-halo-imidazopyridines | |
| CA3221003A1 (en) | Beta-lactam derivatives for the treatment of diseases | |
| CA2588278C (en) | Anthranilamide pyridinureas as vascular endothelial growth factor (vegf)receptor kinase inhibitors | |
| JPWO2010074244A1 (ja) | イソキノリン誘導体 | |
| EP2981519B1 (en) | Process for the preparation of amides from hindered anilines containing a perhaloalkyl group |